We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Italian CART‐SIE real life multicenter observational study on Chimeric Antigen Receptor T‐cell (CAR‐T) therapy for large B‐cell (LBCL) and mantle cell (MCL) lymphomas.
- Authors
Chiappella, A.; Dodero, A.; Ljevar, S.; Pennisi, M.; Bonifazi, F.; De Philippis, C.; Galli, E.; Di Rocco, A.; Tisi, M. C.; Cutini, I.; Carrabba, M. G.; Musso, M.; Martino, M.; Barbui, A. M.; Botto, B.; Farina, M.; Grillo, G.; Patriarca, F.; Ladetto, M.; Arcaini, L.
- Abstract
B Introduction: b Axi-cel and tisa-cel are reimbursed for the treatment of LBCL relapsed/refractory (R/R) after at least two treatments; brexu -cel for R/R MCL failing a BTK inhibitor. In the whole population, all grade CRS was observed in 355/426 (83%) patients, with 47 (11%) severe (grade 3-4); ICANS in 103 (24%) patients, with 39 (9%) severe (grade 3-4). The Italian CART-SIE real life multicenter observational study on Chimeric Antigen Receptor T-cell (CAR-T) therapy for large B-cell (LBCL) and mantle cell (MCL) lymphomas.
- Subjects
CHIMERIC antigen receptors; LYMPHOMAS; T cells; SCIENTIFIC observation; CYTOKINE release syndrome
- Publication
Hematological Oncology, 2023, Vol 41, p519
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_384